Still Needled By Icahn, Forest Nominates Three To Board
The specialty pharma countered the activist investor's June challenge with its own nominees, while defending its diversification strategy.
The specialty pharma countered the activist investor's June challenge with its own nominees, while defending its diversification strategy.